Cargando…
Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer
In locally advanced squamous cell carcinomas of the head and neck (LA-SCCHN), concurrent chemoradiotherapy is an integral part of multimodality management both in the adjuvant and in the definitive settings. Although de-intensification strategies have been propelled to the forefront of clinical rese...
Autores principales: | Szturz, Petr, Wouters, Kristien, Kiyota, Naomi, Tahara, Makoto, Prabhash, Kumar, Noronha, Vanita, Adelstein, David, Van Gestel, Dirk, Vermorken, Jan B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394212/ https://www.ncbi.nlm.nih.gov/pubmed/30847300 http://dx.doi.org/10.3389/fonc.2019.00086 |
Ejemplares similares
-
Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs
por: Butle, Ashwin, et al.
Publicado: (2021) -
Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity
por: Szturz, Petr, et al.
Publicado: (2020) -
Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck
por: Szturz, Petr, et al.
Publicado: (2016) -
Immunotherapy in head and neck cancer: aiming at EXTREME precision
por: Szturz, Petr, et al.
Publicado: (2017) -
Translating KEYNOTE-048 into practice recommendations for head and neck cancer
por: Szturz, Petr, et al.
Publicado: (2020)